1,051 results on '"Pospisilova, Sarka"'
Search Results
202. Abstract 1479: Differential expression of microRNAs in transformation of follicular lymphoma to diffuse large B cell lymphoma
203. Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification
204. Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice
205. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHVmutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI
206. CLL: A Prognostic Model Comprising Only Two Biomarkers (IGHV Mutational Status and FISH-Cytogenetics) Separates Patients with Different Prognosis and Simplifies the CLL-IPI.
207. Analysis of Clonal Evolution in Chronic Lymphocytic Leukemia from Inactive to Symptomatic Disease Prior Treatment Using Whole-Exome Sequencing
208. Reappraising Immunoglobulin Repertoire Restrictions in Chronic Lymphocytic Leukemia: Focus on Major Stereotyped Subsets and Closely Related Satellites
209. Tailored Approaches for Refined Prognostication in Chronic Lymphocytic Leukemia Patients with Mutated Versus Unmutated Immunoglobulin Receptors
210. Low-Burden TP53 Mutations Occur in Chronic Phase of Myeloproliferative Neoplasms Regardless of Hydroxyurea Administration, Disease Type, and JAK2 Status
211. Cellular Mechanisms Regulating CD20 As a Target of Monoclonal Antibody Therapy in B-Lymphoid Malignancies
212. Rituximab Preferentially Eliminates BCR Signaling Proficient Chronic Lymphocytic Leukemia B Cells In Vivo
213. The Role of Microrna-150 in the Prognosis and Transformation of Follicular Lymphoma
214. Oxidative stress as a therapeutic perspective for ATM-deficient chronic lymphocytic leukemia patients
215. Detection of a deletion at 22q11 locus involving ZNF280A/ZNF280B/PRAME/GGTLC2 in B‐cell malignancies: simply a consequence of an immunoglobulin lambda light chain rearrangement.
216. Activation-induced deaminase and its splice variants associate with trisomy 12 in chronic lymphocytic leukemia.
217. Whole-exome sequencing in relapsing chronic lymphocytic leukemia : clinical impact of recurrent RPS15 mutations
218. Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12 : the accompanying chromosome makes a difference
219. Innovation In the prognostication of chronic lymphocytic leukemia : how far beyond TP53 gene analysis can we go?
220. Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors
221. Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma : Impact on EZH2 expression
222. An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors
223. ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia : enrichment in subset #2 is associated with markedly short telomeres
224. Reappraising Immunoglobulin Repertoire Restrictions in Chronic Lymphocytic Leukemia: Focus on Major Stereotyped Subsets and Closely Related Satellites
225. Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: A systematic reappraisal of classic cytogenetic data
226. DecreasedWNT3expression in chronic lymphocytic leukaemia is a hallmark of disease progression and identifies patients with worse prognosis in the subgroup with mutatedIGHV
227. Synthesis and Antimicrobial Evaluation of 1-[(2-Substituted phenyl)carbamoyl]naphthalen-2-yl Carbamates
228. N-Alkoxyphenylhydroxynaphthalenecarboxamides and Their Antimycobacterial Activity
229. Single cell analysis revealed a coexistence of NOTCH1 and TP53 mutations within the same cancer cells in chronic lymphocytic leukaemia patients
230. Abstract 3291: The expression of CD20 on malignant B cells is regulated by chemokine signaling through the CXCR4/SDF-1 axis: implications for targeting the microenvironmental interactions
231. Clinical and pathogenic features of ETV6 -related thrombocytopenia with predisposition to acute lymphoblastic leukemia
232. Ability to downregulate the level of cyclin-dependent kinase inhibitor p27Kip1 after DNA damage is retained in chronic lymphocytic leukemia cells with functional ATM/p53 signaling pathway
233. COBLL1,LPLandZAP70expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates withIGHVmutational status
234. Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression
235. An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors
236. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations
237. Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia
238. Molecular Evidence for Antigen Drive in the Natural History of Mantle Cell Lymphoma
239. Immunoglobulin heavy variable (IGHV) genes and alleles : new entities, new names and implications for research and prognostication in chronic lymphocytic leukaemia
240. Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia
241. Targeted next-generation sequencing in chronic lymphocytic leukemia : a high-throughput yet tailored approach will facilitate implementation in a clinical setting
242. Prognostic relevance of MYD88 mutations in CLL : the jury is still out
243. Unique Versus Common : Disease-Biased Immunoglobulin Gene Repertoires Along with Public Antigen Receptor Stereotypes in Marginal Zone B-Cell Lymphoproliferations
244. CLL with Mutated IGHV4-34 Antigen Receptors Is Clinically Heterogeneous : Antigen Receptor Stereotypy Makes the Difference
245. Next Generation Sequence Immunoprofiling of the T-Cell Repertoire in Chronic Lymphocytic Leukemia Supports Selection By Shared Antigenic Elements
246. ATM Mutations in Major Stereotyped CLL Subsets : Enrichment in Subset #2 is Associated with Unfavourable Outcome
247. Tp63 Contributes to the Apoptosis Resistant Phenotype in Aggressive Chronic Lymphocytic Leukemia
248. EGR2 Mutations in Chronic Lymphocytic Leukemia : A New Bad Player
249. Personalized Modeling of Disease Evolution in CLL : Does Statistical Significance Translate into Predictive Accuracy?
250. EGR2 mutations in chronic lymphocytic leukemiam - a new bad player?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.